Home>>Signaling Pathways>> Others>> Others>>SPL-410

SPL-410 Sale

目录号 : GC37675

SPL-410 是具有口服活性的、强效的、选择性的、羟乙胺类的类信号肽肽酶 2a (SPPL2a) 的抑制剂,其IC50 值为 9 nM。

SPL-410 Chemical Structure

Cas No.:2351886-00-3

规格 价格 库存 购买数量
1mg
¥2,088.00
现货
5mg
¥5,220.00
现货

电话:400-920-5774 Email: sales@glpbio.cn

Customer Reviews

Based on customer reviews.

Sample solution is provided at 25 µL, 10mM.

产品文档

Quality Control & SDS

View current batch:

产品描述

SPL-410 is an orally active, highly potent and selective hydroxyethylamine based SPPL2a (Signal Peptide Peptidase Like 2a) inhibitor, with an IC50 of 9 nM[1]. IC50: 9 nM (SPPL2a)[1].

[1]. Velcicky J, et al. Discovery of Orally Active Hydroxyethylamine Based SPPL2a Inhibitors. ACS Med Chem Lett. 2019 May 23;10(6):887-892.

Chemical Properties

Cas No. 2351886-00-3 SDF
Canonical SMILES N[C@H]([C@@H](O)CN(C1CCC1)S(C2=CC=C(C(C)(C)C)C=C2)(=O)=O)C3=CC=C(OC(F)(F)F)C=C3
分子式 C24H31F3N2O4S 分子量 500.57
溶解度 DMSO : 190 mg/mL (379.57 mM; Need ultrasonic) 储存条件 Store at -20°C
General tips 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。
Shipping Condition 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。

溶解性数据

制备储备液
1 mg 5 mg 10 mg
1 mM 1.9977 mL 9.9886 mL 19.9772 mL
5 mM 0.3995 mL 1.9977 mL 3.9954 mL
10 mM 0.1998 mL 0.9989 mL 1.9977 mL
  • 摩尔浓度计算器

  • 稀释计算器

  • 分子量计算器

质量
=
浓度
x
体积
x
分子量
 
 
 
*在配置溶液时,请务必参考产品标签上、MSDS / COA(可在Glpbio的产品页面获得)批次特异的分子量使用本工具。

计算

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % saline
计算重置

Research Update

Discovery of Orally Active Hydroxyethylamine Based SPPL2a Inhibitors

ACS Med Chem Lett 2019 May 23;10(6):887-892.PMID:31223443DOI:PMC6580379

SPPL2a (Signal Peptide Peptidase Like 2a) is an intramembrane aspartyl protease engaged in the function of B-cells and dendritic cells. Despite being an attractive target for modulation of the immune system, selective SPPL2a inhibitors are barely described in the literature. Recently, we have disclosed a selective, small molecular weight agent SPL-707 which confirmed that pharmacological inhibition of SPPL2a leads to the accumulation of its substrate CD74/p8 and as a consequence to a reduction in the number of B-cells as well as myeloid dendritic cells in mice. In this paper we describe the discovery of novel hydroxyethylamine based SPPL2a inhibitors. Starting from a rather lipophilic screening hit, several iterative optimization cycles allowed for its transformation into a highly potent and selective compound 15 (SPL-410) which inhibited in vivo CD74/p8 fragment processing in mice at 10 mg/kg oral dose.